S33 - Progressive MS Therapeutics

Event Time: Wednesday April 26, 2017 3:30 pm to 5:30 pm
Topic(s): MS and CNS Inflammatory Disease
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
3:54 PM 003 Retinal Nerve Fiber Layer Thickness defines Multiple Sclerosis Patients at Risk of Future Disease Progression Pablo Villoslada
Dr. Villoslada has nothing to disclose.

4:06 PM 004 Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab Michelle Mellion, MD
Dr. Calabresi has nothing to disclose.

4:18 PM 005 Development of a sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Peter Kosa, PhD
Dr. Kosa has nothing to disclose.

4:30 PM 006 The Association Between Confirmed Disability Progression and Patient-Reported Fatigue in PPMS Patients in the ORATORIO study Deborah Miller, PhD
Dr. Miller has nothing to disclose.

4:42 PM 007 Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis: Robert Fox, MD, FAAN
Dr. Fox has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Received compensation for serving as consultant or speaker from Allozyne, Avanir, Biogen Idec, Novartis, Questcor, and Teva Pharmaceutical Industries. Dr. Fox has received research support from Biogen (clinical trial contracts) and Novartis (research study support)..

4:54 PM 008 Long-term Outcomes in Patients with Progressive MS with Relapses: Analysis of TEMSO and TOWER Extension Data Flavia Nelson
Dr. Nelson has nothing to disclose.

Register Now

Related Courses